Douglas Cohen Net Worth

The estimated Net Worth of Douglas Jay Cohen is at least $550 dollars as of 17 August 2021. Mr. Cohen owns over 10,750 units of Organovo Inc stock worth over $550 and over the last 4 years he sold ONVO stock worth over $0. In addition, he makes $0 as Independent Director at Organovo Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Cohen ONVO stock SEC Form 4 insiders trading

Douglas has made over 1 trades of the Organovo Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,750 units of ONVO stock worth $72,348 on 17 August 2021.

The largest trade he's ever made was buying 10,750 units of Organovo Inc stock on 17 August 2021 worth over $72,348. On average, Douglas trades about 1,792 units every 0 days since 2020. As of 17 August 2021 he still owns at least 1,000 units of Organovo Inc stock.

You can see the complete history of Mr. Cohen stock trades at the bottom of the page.

Douglas Cohen biography

Douglas Jay Cohen serves as Independent Director of the Company. He has served as president and Chief Executive Officer of IR Medtek LLC since January 2019, a medical device company developing a non-invasive probe for cancer detection by primary care physicians using a technology licensed from the Ohio State University. Prior to IR Medtek, Mr. Cohen served as President and Chief Executive Officer of Beacon Street Innovations, an advanced technology printing company from September 2016 to present. From January 1994 to September 2016, Mr. Cohen served as Vice President of Operations and Engineering at Screen Machine Industries, an industrial and construction heavy equipment manufacturer. As an active investor in startup companies, Mr. Cohen has invested in over 20 biotech startups in the past 10 years, including investing in Organovo in 2013 and maintaining a position in the company ever since. Mr. Cohen received a B.S. from the Massachusetts Institute of Technology. Mr. Cohen’s experience in the life sciences industry, his experience in managing emerging growth companies and his experience in developing business strategies qualifies him to be appointed as a member of our Board of Directors.

What's Douglas Cohen's mailing address?

Douglas's mailing address filed with the SEC is 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO, CA, 92121.

Insiders trading at Organovo Inc

Over the last 13 years, insiders at Organovo Inc have traded over $8,085,375 worth of Organovo Inc stock and bought 386,250 units worth $661,443 . The most active insiders traders include Mark Kessel, Keith Murphy, and Adam K Stern. On average, Organovo Inc executives and independent directors trade stock every 112 days with the average trade being worth of $29,354. The most recent stock trade was executed by David Gobel on 15 November 2023, trading 19,607 units of ONVO stock currently worth $31,763.

What does Organovo Inc do?

organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.

Complete history of Mr. Cohen stock trades at Organovo Inc

Organovo Inc executives and stock owners

Organovo Inc executives and other stock owners filed with the SEC include:

• Steven Hughes,
  Chief Medical Officer
• Keith Murphy,
  Executive Chairman and Principal Executive Officer
• Steve Kunszabo,
  VP, Investor Relations & Corporate Communications
• Adam Stern,
  Independent Director
• Alison Milhous,
  Independent Director
• David Gobel,
  Independent Director
• Douglas Cohen,
  Independent Director
• Thomas Jurgensen,
  General Counsel
• Jeffrey Miner,
  Chief Scientific Officer
• Chris Heberlig,
  President, Chief Financial Officer
• David Shapiro,
  Director
• Craig Kussman,
  Chief Financial Officer
• Robert Jr. Baltera,
  Director
• Paul Gallant,
  General Manager
• Jennifer Bush,
  General Counsel & Secretary
• Kirk Malloy,
  Director
• Mark Kessel,
  Director
• Taylor Crouch,
  CEO & President
• James T Glover,
  Director
• Sharon Collins Presnell,
  Chief Scientific Officer
• Richard E Maroun,
  Director
• Tamar D Howson,
  Director
• Kevin Kimberlin,
  10% owner
• Richard A. Heyman,
  Director
• Michael Renard,
  EVP of Commercial Operations
• Andras Forgacs,
  Director
• Barry D Michaels,
  Chief Financial Officer
• Eric David,
  CSO & EVP Pre-Clinical Dev
• Carolyn Beaver,
  Director
• Vaidehi Joshi,